title: Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy.
abstract: This study was designed to evaluate the age dependency of 18F-FDG uptake in the thymus and the frequency of PET confirmation of thymus hyperplasia after chemotherapy in cancer patients.
  
  
  METHODS
  Whole-body FDG PET recordings of 168 patients were retrospectively examined for a retrosternal lesion in the anterior mediastinum that was attributable to the thymus. The patients were assigned to the following four groups: children with malignant lesions before the first therapy (group Ia; n = 15; mean age +/- SD, 11.9 +/- 3.7 y), children with malignant disease after chemotherapy (group Ib; n = 12; mean age, 10.3 +/- 5.0 y), adults with histologically confirmed malignant lymphoma before the first therapy (group IIa; n = 37; mean age, 43.9 +/- 16.7 y), and adult lymphoma patients 3 wk to 4 mo after chemotherapy (group IIb; n = 104; mean age, 40.9 +/- 14.6 y).
  
  
  RESULTS
  Increased FDG accumulation in the thymus was seen in 11 patients (73%) of group Ia and 9 patients (75%) of group Ib. Thymus hyperplasia was found in 5 patients (5%) of group IIb. The eldest of these 5 patients was 25 y old. No increased FDG accumulation in the thymus was observed in any of the group IIa patients. In cases of visible FDG uptake in the thymus, standardized uptake values did not exceed 4.
  
  
  CONCLUSIONS
  FDG accumulation in the thymus is a common finding in children and can occasionally be observed in young adults after chemotherapy. Knowledge of the characteristics of a typical retrosternal lesion in conjunction with the clinical history allows avoidance of diagnostic uncertainty and unnecessary procedures.
authors.affiliation: Division of Nuclear Medicine and Department of Diagnostic Radiology, School of Medicine, Albert-Ludwigs University of Freiburg, Freiburg, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Brink
authors.forename: M J
authors.initials: MJ
authors.lastname: Reinhardt
authors.forename: S
authors.initials: S
authors.lastname: Hoegerle
authors.forename: C
authors.initials: C
authors.lastname: Altehoefer
authors.forename: E
authors.initials: E
authors.lastname: Moser
authors.forename: E U
authors.initials: EU
authors.lastname: Nitzsche
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging / Q000188:drug therapy; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D013950:Thymus Gland / Q000000981:diagnostic imaging* / Q000187:drug effects; D013952:Thymus Hyperplasia / Q000139:chemically induced* / Q000000981:diagnostic imaging; D013953:Thymus Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D014055:Tomography, Emission-Computed
chemical_list: D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18